As per MRFR analysis, the Viral Gastroenteritis Market Size was estimated at 2.13 (USD Billion) in 2023. The Viral Gastroenteritis Market Industry is expected to grow from 2.22(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The Viral Gastroenteritis Market CAGR (growth rate) is expected to be around 4.24% during the forecast period (2025-2035).
Key Viral Gastroenteritis Market Trends Highlighted
The Global Viral Gastroenteritis Market is characterized by significant trends that are being driven by an increase in viral infections, heightened awareness of hygiene, and a growing emphasis on vaccination. There has been an increase in the number of gastroenteritis epidemics caused by viruses such as norovirus and rotavirus, particularly in crowded environments like hospitals, nursing homes, and schools. These are among the key market drivers.
As a result of this increasing prevalence, there is a pressing need for effective treatments and preventative measures. Furthermore, market growth is being stimulated by global health initiatives that are designed to enhance sanitation and encourage the adoption of good healthcare practices by decreasing transmission rates. Advancements in diagnostic technologies that enable the rapid detection of viral gastroenteritis, thereby enabling opportune interventions, are among the opportunities to be investigated. Pharmaceutical companies have the opportunity to acquire a substantial market share by investing in research and development for new vaccines, particularly those for norovirus.
Recently, governments worldwide have been partnering with health organizations to raise awareness about the prevention of gastroenteritis, with a particular emphasis on the importance of safe food practices and hand hygiene. This collaborative approach suggests a promising trend in the direction of reducing the burden of viral gastroenteritis on healthcare systems worldwide and fostering a healthier environment.Furthermore, the proliferation of over-the-counter rehydration solutions is becoming a trend as more consumers pursue self-care alternatives.
The incorporation of digital health platforms in the education of the public about the symptoms, transmission, and prevention of viral gastroenteritis is also on the rise, thereby increasing patient engagement and awareness. The market is expected to continue to evolve as global mobility increases, with ongoing research and preventive strategies remaining essential for the effective management of viral gastroenteritis.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Viral Gastroenteritis Market Drivers
Increasing Prevalence of Viral Gastroenteritis
The Global Viral Gastroenteritis Market Industry is significantly driven by the rising prevalence of viral gastroenteritis, which particularly affects children and older adults. According to the World Health Organization (WHO), gastroenteritis is responsible for approximately 1.5 million deaths annually among children under five years of age globally. This alarming statistic, combined with the growing awareness about sanitation and hygiene practices, has increased the demand for effective treatment and prevention options.Organizations such as the Centers for Disease Control and Prevention (CDC) emphasize the need for the development of vaccines and antiviral treatments to curb the spread of viral gastroenteritis, thereby driving growth in the market.
Furthermore, with the global increase in travel and trade, the risk of outbreaks also escalates, driving further investment in the Global Viral Gastroenteritis Market Industry. Efforts from regulatory bodies to ensure food safety and hygiene in public places also contribute to the market's expansion as they create an environment conducive to growth.
Escalating Research and Development Activities
The Global Viral Gastroenteritis Market Industry is experiencing substantial growth due to escalating research and development activities aimed at creating new antiviral therapies and vaccines. Major pharmaceutical companies are investing heavily in research, with reports indicating that global spending on pharmaceutical R has exceeded USD 200 billion in recent years. This surge is driven by technological advancements and an urgent need to address viral infections more effectively.
The National Institutes of Health (NIH) has increased funding for clinical trials focusing on viral gastroenteritis, which supports the advancement of innovative treatment options. The result is a growing pipeline of therapies that are expected to enter the market, catering to the increasing demand for efficient solutions, further propelling growth in the Global Viral Gastroenteritis Market Industry.
Growing Awareness and Education Initiatives
An essential driver for the Global Viral Gastroenteritis Market Industry is the growing awareness and education initiatives regarding the prevention and management of viral gastroenteritis. Health organizations worldwide are actively promoting hygiene practices and vaccination campaigns to educate the public. For example, initiatives led by the WHO and CDC emphasize the importance of hand hygiene and safe food handling to reduce the incidence of viral infections.
In countries with high rates of infection, such as India and Nigeria, educational programs have resulted in a significant decrease in gastroenteritis cases, demonstrating the impact of informed communities. As global efforts continue to spread awareness, the focus on preventive measures enhances demand for relevant health products and services, thus supporting the growth of the Global Viral Gastroenteritis Market Industry.
Viral Gastroenteritis Market Segment Insights
Viral Gastroenteritis Market Type Insights
The Global Viral Gastroenteritis Market, focusing on the Type segment, shows significant diversity in its various classifications, primarily including Norovirus, Rotavirus, Adenovirus, and Sapovirus. As of 2024, the market is valued at 2.22 USD Billion, with individual segments contributing notably to the overall revenue. The Norovirus segment holds a majority share of the market, valued at 0.92 USD Billion, and is anticipated to capture an even larger portion by reaching 1.45 USD Billion in 2035.
This segment is crucial as Norovirus is recognized as a leading cause of gastroenteritis outbreaks, particularly in community settings like schools and cruise ships, showcasing its significant public health impact.Rotavirus follows with a valuation of 0.55 USD Billion in 2024, expected to rise to 0.88 USD Billion by 2035, highlighting its relevance primarily among infants and young children, where it has been known to cause severe dehydration and hospitalization. Adenovirus, meanwhile, is projected at 0.4 USD Billion in 2024, growing to 0.65 USD Billion in 2035, and plays a vital role in contributing to gastrointestinal illnesses, particularly in immunocompromised individuals as well as children.
Lastly, the Sapovirus segment is valued at 0.35 USD Billion in 2024 and is predicted to increase to 0.52 USD Billion by 2035; its impact, although lesser known, cannot be ignored as it is linked to sporadic outbreaks, further complicating the landscape of the Global Viral Gastroenteritis Market.Understanding the segmentation of this market provides valuable insights into the dynamics of viral gastroenteritis, reflecting broader trends in public health as well as highlighting opportunities for prevention and management strategies tailored to specific viral causes.
The interplay among these segments shows how varied the landscape is, with Norovirus dominating the chart, while others like Rotavirus and Adenovirus affirm their importance in the pediatric context as significant contributors to health care costs and disease prevention strategies.Overall, the growth trajectory across these segments within the Global Viral Gastroenteritis Market signifies a crucial area for industry focus and potential investment in targeted interventions and Research and Development initiatives.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Viral Gastroenteritis Market Transmission Route Insights
The Global Viral Gastroenteritis Market has shown significant value, expected to reach 2.22 Billion USD by 2024. Within this market, the Transmission Route segment plays a pivotal role in the spread of viral gastroenteritis, which can have severe health implications. The Fecal-Oral Route is essential as it represents a primary pathway for viral transmission, especially in areas with inadequate sanitation. Contaminated Water is another crucial route, often resulting from environmental contamination and leading to large-scale outbreaks; this makes it a key focus for public health initiatives globally.
Contaminated Food also significantly contributes to viral transmission, with outbreaks often linked to foodborne pathogens. The interplay of these routes contributes to the overall market growth, as increased awareness about hygiene and sanitation enhances preventive measures.
The Global Viral Gastroenteritis Market segmentation reflects these trends, showing that addressing these transmission routes through effective public health policies and education can bolster market growth while providing opportunities to mitigate outbreaks and reduce associated healthcare costs.With globalization and increased travel, focusing on these transmission channels is vital for effectively managing and controlling gastroenteritis cases worldwide.
Viral Gastroenteritis Market Age Group Insights
The Global Viral Gastroenteritis Market is structured around various age groups, including children, adults, and older adults. In 2024, the market is expected to be valued at 2.22 billion USD, highlighting the growing concern for this condition across different demographics. Each age group faces unique challenges and vulnerabilities, with children often being the most affected due to their developing immune systems. Adults represent a significant portion of the population who also contract viral gastroenteritis, frequently linked to lifestyle factors and outdoor activities.
The elderly group is particularly at risk due to weakened immune systems and existing health conditions, underscoring the need for targeted healthcare approaches. The Global Viral Gastroenteritis Market segmentation reflects the importance of addressing each age group distinctly, as the prevention and treatment strategies may differ.
Trends such as urbanization and dietary changes are driving the market's growth, while public health initiatives focused on hygiene and sanitation are critical in mitigating outbreaks. The challenges of rapidly spreading viral strains necessitate continuous Research and Development in treatment options, enhancing the overall response to this common yet impactful illness.
Viral Gastroenteritis Market Treatment Type Insights
The Global Viral Gastroenteritis Market is poised for significant growth, particularly within the Treatment Type segment. By 2024, it is expected to reach a value of 2.22 billion USD, highlighting the increasing demand for effective treatment options. The Treatment Type segment comprises various strategies, including Supportive Care, Antiviral Medications, and Hydration Solutions, each playing a vital role in managing symptoms and complementing recovery.
Supportive Care is essential for symptom relief, often representing a substantial portion of the treatment protocols, while Antiviral Medications are gaining traction as advancements in therapeutics emerge.Additionally, Hydration Solutions are critical, particularly in regions with high incidence rates, as dehydration is a common complication of viral gastroenteritis. The overall market growth is driven by factors such as rising awareness, increased healthcare expenditures, and the prevalence of viral infections globally. However, challenges remain, including variable access to treatments across different regions and the need for ongoing research and development efforts. As the market evolves, opportunities to enhance treatment efficacy and accessibility continue to present themselves.
Viral Gastroenteritis Market Regional Insights
The Global Viral Gastroenteritis Market showcases significant regional dynamics, with North America leading the market landscape with a valuation of 0.85 USD Billion in 2024, which is anticipated to grow to 1.35 USD Billion by 2035. This region's prominence is attributed to a well-established healthcare infrastructure and increased awareness regarding viral infections. Europe follows closely, projected to transition from 0.65 USD Billion in 2024 to 1.05 USD Billion in 2035, driven by rising incidences of viral gastroenteritis and effective public health initiatives.The Asia-Pacific region, valued at 0.5 USD Billion in 2024, is expected to reach 0.8 USD Billion by 2035, reflecting a growing population and improving access to healthcare services.
South America, albeit smaller, is also evolving, from 0.15 USD Billion in 2024 to 0.25 USD Billion in 2035, indicating a gradual focus on healthcare improvement. The Middle East and Africa (MEA), with a current valuation of 0.07 USD Billion in 2024, is projected to decrease slightly to 0.05 USD Billion by 2035, revealing challenges in healthcare accessibility. The diversity in these regional figures illustrates the varying growth drivers, challenges, and opportunities in the Global Viral Gastroenteritis Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Viral Gastroenteritis Market Key Players and Competitive Insights
The Global Viral Gastroenteritis Market is characterized by a dynamic environment where various pharmaceutical companies are vying for a stronghold amidst increasing awareness and rising incidences of viral infections. Several factors, including the development of innovative treatments, the enhancement of vaccine efficacy, and the expansion of healthcare services across different regions, influence this market. Companies are focusing on understanding patient needs, exploring emerging markets, and addressing challenges posed by seasonal outbreaks and viral mutations. Competitive strategies such as mergers, acquisitions, and collaborations are regularly employed as firms aim to strengthen their product portfolios and enhance their reach.
With the pressing concern of viral gastroenteritis globally, there is an increasing urgency to develop effective therapeutic and preventive measures, making this a pivotal area for investment and research within the pharmaceutical industry.Focusing on Pfizer, the company has established itself as a formidable player in the Global Viral Gastroenteritis Market, leveraging its extensive experience in vaccine development and pharmaceutical innovations. Pfizer's strategic positioning is attributed to its commitment to research and development, which has led to the introduction of several well-regarded vaccines that are aimed at preventing viral infections, including those causing gastroenteritis.
Their strong presence in various regions has allowed Pfizer to build a reputation for high-quality products paired with significant market accessibility. The company boasts robust financial resources, which facilitate ongoing investment in cutting-edge therapies and expand its market influence, thereby contributing positively to its overall growth in this sector.Takeda Pharmaceutical has made notable strides in the Global Viral Gastroenteritis Market through a focus on innovative solutions and strategic collaborations. A commitment to research and investment in advanced clinical studies underscores their dedication to developing effective treatments for viral infections.
Takeda offers key products that focus on preventative treatments, aiming to reduce the incidence and severity of gastroenteritis among diverse populations. Their strategic mergers and acquisitions enhance their capabilities in vaccine production and position them favorably within the global market as they integrate new technologies and expertise from their acquired entities. This consolidation allows Takeda to improve its service offerings while also expanding its geographical footprint, ensuring that it remains competitive in addressing the rising demands for effective viral gastroenteritis interventions in the global marketplace.
Key Companies in the Viral Gastroenteritis Market Include
Viral Gastroenteritis Market Industry Developments
The Global Viral Gastroenteritis Market has seen significant developments recently, particularly due to the ongoing impact of viral infections. Companies such as Pfizer, Takeda Pharmaceutical, AbbVie, Roche, Johnson and Johnson, GSK, Hoffmann la Roche, Novartis, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Merck, AstraZeneca, Purdue Pharma, Amgen, and Sanofi have been actively involved in Research and Development initiatives aimed at addressing viral gastroenteritis. A notable merger occurred in September 2023 when AbbVie announced its acquisition of a biotechnology firm specializing in gastrointestinal disorders, expected to strengthen its position in this market.
Additionally, regulatory changes amidst health crises have accelerated vaccine development and distribution, prompting companies to enhance their product portfolios. Noteworthy market growth has been reported, particularly in the North American and European regions, fueled by increasing awareness and proactive healthcare measures. Over the last two years, the market has expanded due to heightened research and awareness regarding foodborne viruses, with significant advancements noted in vaccine technologies and antiviral treatments. Companies are focusing on collaborative partnerships to foster innovation and cater to this critical healthcare demand globally.
Viral Gastroenteritis Market Segmentation Insights
Viral Gastroenteritis Market Type Outlook
Norovirus
Rotavirus
Adenovirus
Sapovirus
Viral Gastroenteritis Market Transmission Route Outlook
Fecal-Oral Route
Contaminated Water
Contaminated Food
Viral Gastroenteritis Market Age Group Outlook
Children
Adults
Elderly
Viral Gastroenteritis Market Treatment Type Outlook
Supportive Care
Antiviral Medications
Hydration Solutions
Viral Gastroenteritis Market Regional Outlook
North America
Europe
South America
Asia Pacific
Middle East and Africa
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 2.13(USD Billion) |
| MARKET SIZE 2024 | 2.22(USD Billion) |
| MARKET SIZE 2035 | 3.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.24% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Pfizer, Takeda Pharmaceutical, AbbVie, Roche, Johnson and Johnson, GSK, HoffmannLa Roche, Novartis, Regeneron Pharmaceuticals, BristolMyers Squibb, Merck, AstraZeneca, Purdue Pharma, Amgen, Sanofi |
| SEGMENTS COVERED | Type, Transmission Route, Age Group, Treatment Type, Regional |
| KEY MARKET OPPORTUNITIES | Increased vaccine development, Rising awareness campaigns, Expansion of diagnostics market, Growth in telemedicine services, Advancements in treatment modalities |
| KEY MARKET DYNAMICS | rising infection rates, increasing healthcare expenditure, vaccine development advancements, growing awareness of hygiene, government initiatives and policies |
| COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
Viral Gastroenteritis Market Highlights:
Frequently Asked Questions (FAQ) :
The Global Viral Gastroenteritis Market is expected to be valued at 2.22 USD Billion in 2024.
By 2035, the market is anticipated to reach a valuation of 3.5 USD Billion.
The expected CAGR for the Global Viral Gastroenteritis Market from 2025 to 2035 is 4.24%.
North America is forecasted to hold the largest market share with a value of 0.85 USD Billion in 2024.
The Norovirus segment is expected to be valued at 0.92 USD Billion in 2024.
The Rotavirus segment is projected to reach a value of 0.88 USD Billion by 2035.
Key players in the market include Pfizer, Takeda Pharmaceutical, AbbVie, and Roche among others.
The Adenovirus segment is anticipated to be valued at 0.4 USD Billion in 2024.
The market in South America is expected to grow to a value of 0.25 USD Billion by 2035.
The Sapovirus segment is expected to be valued at 0.35 USD Billion in 2024.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
